Monday, December 10, 2007

Marketing in domestic formulations has become a competitive function

M&A the main driver for value unlocking in Indian pharma

‘Generics’ is the old story in the great Indian pharmaceutical space. The new kids on the block are ‘contract research and manufacturing services’ (CRAMS) providers.

The emphasis is on future leaders rather than established captains, and the rapid expansion plans charted by these emerging breeds make them a perfect fit for private equity players, who are hot on heels to get their slice of the growing pie.

Naturally, funding is less of an issue for these smaller companies, says Mr Navroz Mahudawala, Associate Director, Transaction Advisory Service of Ernst & Young (E&Y).

No comments: